Healthcare

What follows is a balanced, general overview of the company and its setting, including possible drivers of interest and the uncertainties that investors may wish to weigh for themselves. It does not constitute financial advice.

What follows is a balanced, general overview of the company and its setting, including possible drivers of interest and the uncertainties that investors may wish to weigh for themselves. It does not constitute financial advice.

What follows is a balanced, general overview of the company and its setting, including possible drivers of interest and the uncertainties that investors may wish to weigh for themselves. It does not constitute financial advice.

What follows is a balanced, general overview of the company and its setting, including possible drivers of interest and the uncertainties that investors may wish to weigh for themselves. It does not constitute financial advice.

What follows is a balanced, general overview of the company and its setting, including possible drivers of interest and the uncertainties that investors may wish to weigh for themselves. It does not constitute financial advice.

The global leader in allogeneic cellular medicines for inflammatory diseases said the result reflects strong and continuing uptake of Ryoncil since its launch, with revenue already ahead of the company's initial internal projections. Chief Executive Dr Silviu Itescu said the company anticipates further revenue …

Mesoblast Ltd (ASX: MSB) is a biotechnology company specialising in regenerative medicine through the development of allogeneic cell therapies. Rather than focusing on traditional pharmaceutical products, the company develops treatments designed to address inflammatory, immune-mediated and degenerative diseases using proprietary cellular technologies.